ClinicalTrials.gg
RecruitingNCT06518499Updated Oct 8, 2024

Outcomes of Karydakis, Primary Closure, and Pit Picking Methods in the Treatment of Pilonidal Sinus: A Prospective Study in Women

An observational study in Pilonidal Sinus, sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
145
Ages
18 Years and older
Sex
Female
01

Study summary

Although there are many methods for the surgical treatment of pilonidal sinus disease, the number of studies specific to women is limited in the literature. In addition to post-treatment recurrence and complication rates in women, aesthetic results are also of great importance. This study will compare the Karydakis procedure, a flap method, and the Bascom's pit-pick procedure, a minimally invasive procedure, in terms of recurrence, complications and aesthetics, especially in female patients with three or fewer pits.

Read the detailed description

This study is a single-center, prospective observational trial aimed at comparing the effectiveness of the Karydakis flap and Bascom's pit-pick methods in treating pilonidal sinus disease in women. Female patients aged 18 and over, with three or fewer pits, will be included, and each patient will be followed for 12 months. The Bascom pit-pick method will be performed under local anesthesia, while the Karydakis method will be performed under spinal or general anesthesia. Postoperative recovery time, complications, recurrence rates, and patient satisfaction will be evaluated. Ethics committee approval has been obtained (Approval No: TE 172, Date: June 12, 2024).

02

Conditions studied

  • Pilonidal Sinus

Browse trials for

03

In context

Pilonidal Sinus

109 studies on the registry are indexed under Pilonidal Sinus; 32 are open to participants now.

This study's planned enrollment of 145 is close to the median of 145 across 37 observational studies indexed under Pilonidal Sinus.

Browse Pilonidal Sinus studies →

Lead sponsor

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital is the lead sponsor of 41 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Female patients aged 18 and older with pilonidal sinus disease and three or fewer pits, with no previous surgical treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients 18 years old and older
  • Diagnosed with pilonidal sinus disease, having 3 or fewer pits.
  • No previous surgical treatment for pilonidal sinus.

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • Pregnancy
  • Presented with acute abscesses
  • Patients with recurrent disease, Stage-R.
  • >3 pit
  • Collagen tissue disease
  • Exceed to navicular area
  • Lateral extension in both directions
  • Accidentally discovered (asymptomatic) sinus or with follow-up \<12 months
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
145 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Bascom's Pit-Pick procedure

    The Bascom pit-pick procedure is performed under local anesthesia with the patient in a prone position, taking approximately 15-20 minutes. Pre-operative preparation includes shaving and cleaning the surgical area. Local anesthesia (lidocaine with adrenaline) is typically used, with general anesthesia as an alternative if needed. The surgical technique involves excising midline pits with a scalpel, removing infected granulation tissue and hairs through curettage or a lateral incision. Midline wounds and nearby secondary pits are sutured with polypropylene, while the lateral incision is left open and covered with a hydrofibre bandage to heal by secondary intention.

    Procedure: Pilonidal sinus surgery

  • Primary Closure

    The primary closure technique for pilonidal sinus involves placing the patient in a prone position under spinal or general anesthesia, shaving and cleaning the surgical area, and making an elliptical incision to remove the affected tissue. A skin flap is then mobilized from the surrounding area to cover the excision site, and the wound is closed with sutures.

    Procedure: Pilonidal sinus surgery

  • Karydakis

    The Karydakis primary closure procedure involves placing the patient in a prone position under spinal or general anesthesia. The surgical area around the natal cleft is shaved and cleaned thoroughly. A symmetric elliptical excision is performed 2 cm lateral to the midline, removing all affected pilonidal sinus tissue and some surrounding normal tissue. A skin flap, 2 cm wide and 1 cm thick, is mobilized from the contralateral side to cover the resultant defect. The flap is secured using a continuous suture technique, with the skin closed using polypropylene mattress sutures. A low-suction drain is used to standardize the procedure, removed when drainage decreases to less than 20 ml/day.

    Procedure: Pilonidal sinus surgery

Interventions

  • ProcedurePilonidal sinus surgery

    Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure

06

What researchers measure

Primary outcomes

  1. Recurrence Rate

    This measure evaluates the rate of pilonidal sinus disease recurrence in female patients undergoing Karydakis flap or Bascom's pit-pick surgical procedures over a 12-month period. Recurrence is defined as the reappearance of disease symptoms after the wound has completely healed.

    Time frame: 12 months post-surgery

Secondary outcomes

  1. Complication Rate

    This measure records the incidence of postoperative complications such as infections (superficial or deep), seromas, hematomas, wound dehiscence (partial or complete), and anesthesia-related complications within the first 30 days post-surgery.

    Time frame: 30 days post-surgery

  2. Aesthetic Outcome (Visual Analog Score for pain)

    Assessment of aesthetic outcomes using the Visual Analog Scale (VAS) for pain. The VAS is a scale from 0 to 10, where 0 represents no pain and 10 represents the worst possible pain. Higher scores indicate worse outcomes.

    Time frame: Up to 1 year post-surgery

  3. Healing Time

    This measure records the time required for complete wound healing post-surgery, defined as the integrity along the incision line without any complications.

    Time frame: Up to 12 weeks post-surgery

  4. Functional Recovery

    This measure assesses the time taken for patients to resume daily activities comfortably.

    Time frame: Up to 24 weeks post-surgery

07

Study locations

1 of 1 sites recruiting
  • Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital
    İstanbul, Other, Turkey
    Recruiting
    • Adnan Gundogdu · Contact
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 24, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jul 1, 2026
CompletionEst.
Aug 20, 2026
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06518499
Lead sponsor
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Jul 1, 2024
Primary completion
Jul 1, 2026 (estimated)
Completion
Aug 20, 2026 (estimated)
Last update
Oct 8, 2024

Study contacts

Adnan Gundogdu
Contact
adnangundogdu89@gmail.com
+905367173909

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion